Clinical Significance of Primary Tumor Resection in Patients with Metastatic Urothelial Carcinoma at Initial Presentation by 堀, 淳一 et al.
Title初診時に転移を有する進行性尿路上皮癌における原発巣摘除の意義
Author(s)堀, 淳一; 玉木, 岳; 安住, 誠; 柿崎, 秀宏









堀 淳一，玉木 岳，安住 誠，柿崎 秀宏
旭川医科大学腎泌尿器外科学教室
CLINICAL SIGNIFICANCE OF PRIMARY TUMOR RESECTION
IN PATIENTS WITH METASTATIC UROTHELIAL
CARCINOMA AT INITIAL PRESENTATION
Jun-ichi Hori, Gaku Tamaki, Makoto Azumi and Hidehiro Kakizaki
The Department of Renal and Urologic Surgery, Asahikawa Medical University
We retrospectively reviewed 67 patients who presented with metastatic urothelial carcinoma to the
Department of Urology, Asahikawa Medical University Hospital between 2000 and 2013. Furthermore, 13
patients with comparatively longer survival (2 years or longer after diagnosis) were analyzed to ﬁnd any
clinical characteristics among these patients. The primary site was the upper tract in 41 patients and
bladder in 26. The most frequent metastatic site was regional lymph nodes (49 patients), followed by viscera
(36 patients) and distant lymph nodes (17 patients). Primary tumor resections were performed on 83% of
the patients with only regional lymph node metastasis, but on only 35% of the patients with distant metastasis.
Median overall survival (OS) of patients was 8.5 months in this series. Median OS of patients with only
regional lymph node metastasis was 15 months, which was signiﬁcantly longer than that (8 months) of
patients with distant metastasis. Multivariate analysis revealed only regional lymph node metastasis and the
number of metastatic sites were signiﬁcant prognostic factors for OS. We further investigated the clinical
characteristics of 13 patients with comparatively longer survival. Other than a small number of metastatic
sites (1 or 2) and no distant lymph node metastasis, we could not ﬁnd any signiﬁcant characteristics to predict
longer prognosis. The present study showed that primary tumor resection did not have a signiﬁcant beneﬁt
on survival in patients with metastatic urothelial carcinoma at initial presentation. However, primary tumor
resection should be considered when there is only regional lymph node metastasis and few metastatic sites.
(Hinyokika Kiyo 62 : 1-7, 2016)


































患者背景を Table 1 に示す．原発巣は上部尿路が
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Table 1. Clinical characteristics of 67 patients
Factors Median (range or ％)
Follow up (month) 10 (2-96)
No cases 67
Age 69 (56-86)
Men to women ratio 3 : 1
Primary site
Upper urinary tract 41 (61％)
Bladder 26 (39％)
Metastatic site at initial visit
Regional lymph node 49
Organ 36
Distant lymph node 17
No metastasis 1 (1-5)




Regional Lymph node metastasis alone 23 15
Chemotherapy→primary resection 6 23.5
Primary resection→chemotherapy 8 28
Primary resection alone 5 4
No operation (only chemotherapy or
radiation) 3 13
No treatment 1 9
Distant metastasis 44 8
Chemotherapy→primary resection 7 9.5
Primary resection→chemotherapy 5 55.5
Primary resection alone 4 7
No operation (only chemotherapy or
radiation) 25 7
.5
No treatment 3 3.5
泌61,01,0◆-1
Fig. 1. Overall survival of all 67 patients.
61％を占めていた．転移巣は，所属リンパ節転移が最
も多く，次いで臓器転移，遠隔リンパ節転移の順で
あった．転移巣数は中央値で 1（ 1∼ 5）であった．
臓器転移部位は，肺21例，骨17例，肝臓15例，副腎 6
例，脳 3例であった（重複例あり）．治療内容を具体







生存曲線を Fig. 1 に示す．全67症例の全生存率（以
下，OS）は中央値で8.5カ月であった．遠隔転移の有
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Fig. 3. a : Overall survival according to primary tumor resection
in M0 cases. b : Overall survival according to primary
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Fig. 4. Overall survival according to lymph node dissection in M0
cases.
Table 3. Multivariate analysis for prognostic factors
(Cox proportional hazard model)
Factors PRC HR 95％ CI P value
Primary
resection
−0.4890 0.6133 0.2458-1.5299 0.2945
LND −0.5734 0.5636 0.2199-1.4441 0.2323
Regional LN
meta
−1.2412 0.2890 0.0956-0.8738 0.0279
Distant LN
meta 0
.6527 1.9207 0.8835-4.1757 0.0995
Organ meta −0.9061 0.4041 0.1419-1.1509 0.0897
Primary site −0.2190 0.8033 0.4396-1.4679 0.4764
No meta 0.5567 1.7448 1.1376-2.6762 0.0108
PRC : partial regression coefﬁcient, LND : lymph node dissec-
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Table 4. Clinical and pathological characteristics of 13 patients with comparatively longer survival (2 years or longer)
Primary site Regional LN Distant LN Organ No meta Primary resection LND stage NAC AC Mx Prognosis
B ＋ − − 1 − − Chemotherapyalone 50m death
R ＋ − − 1 ＋ ＋ T3N1M0 − ＋ 28m death
R ＋ − − 1 ＋ ＋ T3N0M0 ＋ ＋ 30m death
R ＋ − − 1 ＋ ＋ T3N2M0 − ＋ Lung 35m death
R ＋ − − 1 ＋ ＋ T4N2M0 − ＋ 96m alive
B ＋ − Bone 2 − − Chemotherapyalone 45m death
B − − adr 1 ＋ ＋ T3N2M1 − ＋ Bone 25m death
R ＋ − Bone 2 ＋ ＋ T4N2M1 − ＋ 82m alive
U ＋ − − 1 ＋ ＋ T2N2M0 − ＋ 45m alive
R ＋ − − 1 ＋ ＋ T3N1M0 − ＋ 39m alive
U ＋ − Lung 2 − − Chemotherapyalone 26m death
U − − Lung 1 ＋ − T2NXM1 − ＋ 29m death
B ＋ − − 1 ＋ ＋ T3N1M0 ＋ ＋ 24m alive
B : Bladder, R : Renal pelvis, U : Ureter, adr : adrenal gland, LN : lymph node, LND : lymph node dissection, NAC : neoadjuvant
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